Navigating CAR T-Cell Therapy Referrals: Bijal Shah, MD; Michael Wang, MD
The hematologists from Moffitt Cancer Center and University of Texas MD Anderson Cancer Center discussed navigating the referral process for CAR T-cell therapy in hematologic malignancies.
This content originally appeared on our sister site, OncLive.
OncLive spoke with Bijal Shah, MD, MS, associate member, Department of Malignant Hematology, Moffitt Cancer Center, and Michael Wang, MD, professor, Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, to learn more about how to navigate the referral process for chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.
Shah touched on the difficulties of this process. Patients who receive CAR T-cell therapy are expected to stay in or around the treatment center for 2 to 4 weeks, depending on the severity of CAR T-cell therapy–related toxicities, Wang said.
Ultimately, close collaboration between community and academic practices is needed to ensure the referral process is optimal for patients, Shah and Wang conclude.
Transplant Eligibility Versus CAR-T Eligibility
January 16th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.
Sequencing of Treatment in Third-Line R/R LBCL
January 15th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.
